Latest Results from Immunotherapy Clinical Trials in Triple Negative Breast Cancer
DOI:
https://doi.org/10.17140/CTPOJ-2-105Keywords:
Cancer, Immunotherapy, Triple negative breast cancer (TNBC), Breast cancerAbstract
Cancer immunotherapy has evolved enormously in the recent years with better understanding of immune reactions, immune microenvironment
and immunosurveillance. Breast cancer is characterized by large heterogeneity, a fact which rather complicated
the development and the approval of novel therapeutic options in comparison to the majority of other solid tumors since each
subtype has required a unique scientific approach and different targets and goals. Triple negative breast cancer (TNBC) is considered
the most aggressive of the breast cancer subtypes with limited treatment options and worse outcome compared to others.
This article summarizes some of the early clinical studies and the recently presented phase III clinical study of immunotherapy
checkpoint inhibitors in this difficult setting.
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67: 7-30. doi: 10.3322/caac.21387
Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Tri-ple-negative breast cancer: challenges and opportunities of a het-erogeneous disease. Nat Rev Clin Oncol. 2016; 13: 674-690. doi: 10.1038/nrclinonc.2016.66
Cimino-Mathews A, Foote JB, Emens LA. Immune targeting in breast cancer. Oncology (Williston Park). 2015; 29: 375-385.
Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: From TILs to clinic. Nat Rev Clin Oncol. 2016; 13: 228-241. doi: 10.1038/nrclinonc.2015.215
Dirix L, Takacs I, Nikolinakos P, et al. Avelumab (MSB0010718C), and an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase 1b JAVELIN solid tumor study. Paper presented at: 38th Annual CTRC-AACR aan antonio breast cancer symposium; December 8-12, 2016; San Antonio, TX. Phil-adelphia (PA), USA.
Nanda R, Specht J, Dees EC, et al. KEYNOTE-012: long-lasting responses in a phase 1b study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC). Paper presented at: 38th Annual CTRC-AACR aan antonio breast cancer symposium; De-cember 6-10, 2016; San Antonio, TX. Philadelphia (PA), USA.
Schmid P, Cruz C, Braiteh FS, et al. Atezolizumab in metastat-ic triple-negative breast cancer: Long-term clinical outcomes and biomarker analyses. Paper presented at: American Association for Cancer Research Annual Meeting 2017; April 1-5, 2017; Wash-ington, DC. Philadelphia (PA), USA. doi: 10.1158/1538-7445. AM2017-2986
Adams S, Dieras V, Barrios CH, et al. Patient-reported outcomes (PROs) from the phase III IMpassion130 trial of atezolizumab (atezo) plus nab-paclitaxel (nP) in metastatic triple-negative breast cancer (mTNBC). Paper presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago, IL, USA. doi: 10.1200/JCO.2019.37.15_ suppl.1067
Tolaney S, Savulsky C, Aktan G, et al. Phase 1b/2 study to eval-uated eribulin mesylate in combination with pembrolizumab in pa-Submit your article to this journal | https://openventio.org/submit-manuscript/ 13 Strimpakos A, et al tients with metastatic triple-negative breast cancer. Paper presented at: San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, TX. Philadelphia (PA), USA.
US National Library of Medicine. Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355). Web site. https://clinicaltrials.gov/ct2/show/NCT02819518. Ac-cessed June 11, 2019.
Schneeweiss A, et al. IMpassion130: expanded safety analysis from a P3 study of atezolizumab (A) + nab-paclitaxel (nP) in pa-tients (pts) with treatment (tx)-naïve, locally advanced or metastatic triple-negative breast cancer (mTNBC). Paper presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago, IL, USA. doi: 10.1200/JCO.2019.37.15_suppl.1068
Schmid P, Adams S, Rugo HS, et al. IMpassion130: Updated overall survival (OS) from a global, randomized, double- blind, placebo-controlled, phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC). Paper present-ed at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago, IL, USA.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Clinical Trials and Practice – Open Journal (CTP) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
